Key result
This review defines hemodialysis-associated cardiomyopathy as a unique disease entity and explores dialysis-based interventions to mitigate ischemic insults from conventional hemodialysis.
This review defines hemodialysis-associated cardiomyopathy as a unique disease entity and explores dialysis-based interventions to mitigate cumulative ischemic insults.
Proposes hemodialysis-associated cardiomyopathy as a distinct entity; hypothesis-generating for dialysis interventions, requiring prospective trials before practice change.
Cardiovascular disease is the most common cause of the greatly elevated rates of mortality characteristic of patients undergoing maintenance hemodialysis. This article is an attempt to describe the complex and evolving features of cardiac disease routinely encountered in HD patients. Furthermore, by trying to appreciate the pathophysiological drivers, and the crucial interaction with the HD treatment itself, this article seeks to define cardiac disease in this setting (HD-associated cardiomyopathy) as a unique and complex entity. By understanding the phenotype and basis of HD-associated cardiomyopathy, we can develop an evolved understanding of the dominant processes involved in its development and offer up dialysis-based interventions specifically designed to mitigate the cumulative ischemic insults consequent to conventional HD treatment. This article explores the justification of this approach and recent evidence of its efficacy.
No takes yet. Share an insight, caveat, or question.
McIntyre et al. (2014) conducted a review in Hemodialysis-associated cardiomyopathy. Dialysis-based interventions vs. Conventional hemodialysis was evaluated. This review defines hemodialysis-associated cardiomyopathy as a unique disease entity and explores dialysis-based interventions to mitigate ischemic insults from conventional hemodialysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: